In a pregnant patient with rheumatic heart disease, severe mitral regurgitation and tricuspid regurgitation, mild global hypokinesia, and left ventricular ejection fraction of 50% who is on standard heart‑failure therapy, which medications should be discontinued?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medication Management in Pregnant Patient with Rheumatic Heart Disease and Heart Failure

Immediately discontinue ACE inhibitors, ARBs, ARNi (angiotensin receptor-neprilysin inhibitors), spironolactone (or any mineralocorticoid receptor antagonists), ivabradine, and SGLT2 inhibitors if the patient is on any of these medications. 1, 2

Medications to DISCONTINUE

The following heart failure medications are contraindicated in pregnancy and must be stopped as soon as pregnancy is confirmed:

  • ACE inhibitors (e.g., enalapril, lisinopril)
  • Angiotensin receptor blockers (ARBs) (e.g., losartan, valsartan)
  • Angiotensin receptor-neprilysin inhibitors (ARNi) (e.g., sacubitril/valsartan)
  • Mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone)
  • Ivabradine
  • SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin)

1, 2

These medications carry risks of fetal embryopathy, fetopathy, renal dysfunction, and other teratogenic effects. The urgency of discontinuation cannot be overstated—stop these immediately upon pregnancy confirmation, even if this means temporarily accepting suboptimal heart failure control.

Medications to CONTINUE

Beta-blockers should be continued throughout pregnancy 1, 2. The preferred agents are:

  • Metoprolol
  • Carvedilol
  • Bisoprolol

These are safe in pregnancy and essential for rate control, especially given the risk of atrial fibrillation in rheumatic heart disease with severe MR/TR. Do not discontinue beta-blockers unless the patient develops acute decompensated heart failure requiring inotropic support 2.

Diuretics (furosemide) should be continued as needed for volume management and congestive symptoms 3, 2. Given the severe regurgitant lesions and mild hypokinesia, diuretics will likely be necessary throughout pregnancy.

Safe Alternatives for Afterload Reduction

Since ACE inhibitors/ARBs must be stopped, substitute with hydralazine and/or isosorbide dinitrate for afterload reduction 1, 2. This combination is pregnancy-safe and provides hemodynamic benefit in regurgitant lesions.

Anticoagulation Considerations

Given the rheumatic etiology, assess for:

  • Atrial fibrillation: If present, therapeutic anticoagulation is mandatory 3
  • Left atrial enlargement/thrombus: Common in rheumatic disease with severe MR
  • EF 50% with global hypokinesia: Consider prophylactic anticoagulation

If EF drops below 35% or if atrial fibrillation develops, pharmacologic thromboprophylaxis is recommended throughout pregnancy and for 6 weeks postpartum 2.

Critical Monitoring Points

This patient requires multidisciplinary care at a center with expertise in cardiac disease in pregnancy 1, 2. The combination of:

  • Severe valvular disease (MR + TR)
  • Reduced systolic function (EF 50% with hypokinesia)
  • Rheumatic etiology (risk of progression, atrial fibrillation)

...places her at high risk for decompensation during the hemodynamic stress of pregnancy, particularly in the second trimester and peripartum period.

Common Pitfalls to Avoid

  1. Do not continue spironolactone "just for a few more weeks"—it causes anti-androgenic effects and should be stopped immediately 1

  2. Do not stop beta-blockers thinking they will harm the fetus—they are safe and essential for maternal cardiac stability 1, 2

  3. Do not use ACE inhibitors even briefly in the first trimester—embryopathy risk exists throughout, though renal effects are worse in second/third trimesters 1

  4. Do not forget to reassess the need for valve intervention—severe symptomatic valvular disease may require percutaneous mitral commissurotomy during pregnancy if medical therapy fails 3

Medication Summary Table

Medication Class Action Rationale
ACE-I/ARB/ARNi STOP Teratogenic, fetal renal dysfunction
Spironolactone/MRA STOP Anti-androgenic effects
Ivabradine STOP Contraindicated in pregnancy
SGLT2 inhibitors STOP Contraindicated in pregnancy
Beta-blockers CONTINUE Safe, essential for rate control
Diuretics CONTINUE Safe, needed for volume management
Hydralazine/Nitrates ADD Safe afterload reduction alternative

The patient should be transitioned to pregnancy-safe medications within days of pregnancy confirmation, with close monitoring for decompensation during the medication switch 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.